140 related articles for article (PubMed ID: 32275165)
1.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
2. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
Holmberg LA; Maloney DG; Connelly-Smith L
Acta Haematol; 2024; 147(3):300-309. PubMed ID: 37708877
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
[TBL] [Abstract][Full Text] [Related]
6. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Feb; 24(2):282-287. PubMed ID: 29061536
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
Auger-Quittet S; Duny Y; Daures JP; Quittet P
Cancer Med; 2014 Aug; 3(4):927-38. PubMed ID: 24740968
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.
Krishnan AY; Palmer J; Nademanee AP; Chen R; Popplewell LL; Tsai NC; Sanchez JF; Simpson J; Spielberger R; Yamauchi D; Forman SJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):922-929. PubMed ID: 28267593
[TBL] [Abstract][Full Text] [Related]
9. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Stuver R; Mian A; Brown S; Devlin S; Caimi PF; Chinapen S; Dahi P; Dean R; Epstein-Peterson ZD; Hill B; Horwitz SM; Lahoud O; Lin R; Moskowitz AJ; Sauter C; Shah G; Winter A; Jagadeesh D; Scordo M
Am J Hematol; 2024 Jun; 99(6):1180-1183. PubMed ID: 38526002
[TBL] [Abstract][Full Text] [Related]
10. A case of peripheral T-cell lymphoma in which therapy-related myelodysplastic syndrome developed and a second autologous transplantation was performed.
Nakagawa SI; Nukii Y; Mochizuki K; Uchiyama A; Maeda Y; Kurokawa T
J Clin Exp Hematop; 2024 Mar; 64(1):59-64. PubMed ID: 38417872
[TBL] [Abstract][Full Text] [Related]
11. Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
Dahi PB; Kenny S; Flynn J; Devlin SM; Ruiz JD; Chinapen SA; Lahoud OB; Matasar MJ; Moskowitz CH; Perales MA; Shah G; Sauter CS; Giralt SA; Geyer AI; Jakubowski AA
Leuk Lymphoma; 2023 Dec; 64(14):2279-2285. PubMed ID: 37690007
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.
Zhang MM; Gopal AK
Semin Hematol; 2008 Apr; 45(2):118-25. PubMed ID: 18381107
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation.
Dahi PB; Lin A; Scordo M; Flynn JR; Devlin SM; Ruiz JD; DeRespiris L; Carlow D; Cho C; Lahoud OB; Perales MA; Sauter CS; Boelens JJ; Admiraal R; Giralt SA; Shah GL
Transplant Cell Ther; 2022 Aug; 28(8):485.e1-485.e6. PubMed ID: 35545213
[TBL] [Abstract][Full Text] [Related]
14. A Deeper Depth of Response After Salvage Therapy Improves Outcomes of Autologous Stem Cell Transplantation in Relapsed Lymphoma and the Feasibility of Non-controlled Rate Freezing of Peripheral Blood Stem Cells.
Rab SU; Ali M; Mahar UR; Ahsan B; Ahmad U; Tariq Mahmood M; Siddiqui N; Bokhari SW
Cureus; 2024 Mar; 16(3):e56851. PubMed ID: 38659569
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S; Ambinder RF
CA Cancer J Clin; 2018 Mar; 68(2):116-132. PubMed ID: 29194581
[TBL] [Abstract][Full Text] [Related]
16. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin's lymphoma: post- autologous transplantation consolidation therapy.
Merli F; Ballerini F; Botto B; Gotti M; Pavone V; Pulsoni A; Stefani PM; Massaro F; Viviani S
Acta Biomed; 2020 May; 91(S-5):23-29. PubMed ID: 32525131
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma.
Al-Hadidi SA; Lee HJ
JCO Oncol Pract; 2021 Feb; 17(2):64-71. PubMed ID: 33434064
[TBL] [Abstract][Full Text] [Related]
19. Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases.
Maqbool S; Baloch MF; Khan MAK; Khalid A; Naimat K
World J Transplant; 2024 Mar; 14(1):87532. PubMed ID: 38576761
[TBL] [Abstract][Full Text] [Related]
20. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
Smith SM; Schöder H; Johnson JL; Jung SH; Bartlett NL; Cheson BD;
Leuk Lymphoma; 2013 Jul; 54(7):1405-10. PubMed ID: 23194022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
